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Despite widespread recognition of the importance of long-term
glycemic control, it has been recently reported that only a low
percentage (about 1/2) of patients with diabetes (DM) had their
glycated hemoglobin (HbA1c) values known or measured when
hospitalized for acute myocardial infarction (AMI) [1].
Data on the prognostic role of HbA1c in AMI patients are still
controversial [1–6] since studies mainly differ for patients' selection
criteria, therapy (thrombolysis vs mechanical revascularization) and
number consistency.
We aimed at assessing the prognostic role of HbA1c for mortality
at short and long terms in 195 consecutive diabetic with ST-elevation
myocardial infarction (STEMI), all submitted to mechanical revascu-
larization and consecutively admitted to our Intensive Cardiac Care
Unit (ICCU) from 1st January 2008 to 30th June 2010 [7–12].
On ICCU admission, after PCI, in a fasting blood sample the following
parameters were measured: glucose (mg/dl), insulin values (UI/l), C-
peptide (ng/ml), Hb A1c(%) troponin I (ng/ml), insulin (mU/l), uric acid
(mg/dl), C-reactive protein (mg/dl) (normal valuesb9), alanine amino-
transferase (ALT, UI/l), aspartate amino transferase (AST, UI/l) [13],
gamma-glutamyl transferase (GGT, UI/l) [14] NT-pro Brain Natriuretic
Peptide (NT-pro BNP) (pg/ml) [11] total cholesterol (mg/dl), triglycer-
ides (mg/dl), HDL, LDL, and fibrinogen (mg/dl). Creatinine (mg/dl) was
alsomeasured in order to calculate glomerular filtration rate (eGFR, ml/
min/1.73 m2) [15]. Nadir eGFR was also recorded. Glucose, Tn I were
measured three times a day during ICCU stay and peak values for each
variable were considered. Acute insulin resistance was measured by
means of the Homeostatic Model Assessment (HOMA) index, as
previously described [10,16–18].
The study protocol was in accordance with the Declaration of
Helsinki and approved by the local Ethics Committee. Informed
consent was obtained in all patients before enrollment.
Data are reported as frequencies (percentages) and medians (95%
Confidence Interval— CI) and analyzed by means ofχ2 (or Fisher's exact
text, when predicted counts in almost one cell were less than 5) for
categorical variables and Mann–Whitney U-test for continuous variables
(that, at Kolmogorov–Smirnov normality test, resulted almost all non-
normally distributed), respectively. Multivariable logistic regression
analyses were carried out considering as outcome intra-ICCU mortality.
Models' calibration was assessed by means of Hosmer–Lemeshow
goodness-of-fit tests as well as plotting the area under the Receiver
Operating Characteristic (ROC) curve (AUC); Nagelkerke R squares are
also reported. Long time survival was explored, after proportionality of
risk assessment,withCox regression analysis, bothwithHbA1c as the sole
candidate variable and in a multivariable manner. In all multivariable
analyses candidate variables were chosen as those considered clinically
relevant or that showed a univariate relationship with outcome;
nonsignificant ones were dropped by means of backward selection.
HbA1c was forced into the analyses. (SPSS 13.0 statistical package, SPSS
Inc, Chicago, IL). A p valueb0.05 was considered statistically significant.
Males were prevalent (67.2%) and hypertensionwas detectable in
the 75.4%. Anterior myocardial infarction was the most frequently
observed (53.8%). In-hospital mortality rate was 3.1%.
Hb A1c≥6.5 was detectable in the 55.9% (Table 1). Patients with
Hb A1c≥6.5 showed higher values of admission and peak glucose
(pb0.001 and pb0.001, respectively), of insulin (pb0.001) and
incidence of HOMA positivity (pb0.001). Higher values of ALT, AST
(pb0.001 and p=0.05, respectively) and ESR (p=0.049) were
observed in patients with Hb A1c≥6.5. No difference was observed
in in-hospital mortality rate between the two subgroups.
At multivariable analysis eGFRwas independently associatedwith in-
hospital death [eGFR(1 ml/min/1.73 m2 increase): O.R.1.96: 95%CI 0.92 to
0.99, pb0.014]. HbA1c≥6.5% (O.R. 2.28: 95%CI 0.31 to 11.53, p=0.495).
Hosmer and Lemeshow testχ2=2.92, p=0.940; Nagelkerke R square=
0.22; area under the ROC curve 0.88 (95%CI 0.80 to 0.96, p=0.002).
At Cox regression analysis, the following variables were inde-
pendently associated with long-term mortality: Age (1 year step)
(H.R. 1.08: 95%CI 1.05 to 1.11, pb0.001); LVEF at discharge (1% step)
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(H.R. 0.94 95%CI 0.91 to 0.98, p=0.002). HbA1c≥6.5% (H.R. 1.79
95%CI 0.88 to 3.64, p=0.107).
The main finding of our investigation performed in consecutive
diabetic STEMI patients submitted to mechanical revascularization,
is that HbA1c values are not related to mortality, both at short and
long term.
Data on this topic are so far scarce and controversial.
In AMI patients with diabetes, the two Diabetes Insulin Glucose
in Acute Myocardial Infarction studies both showed that increasing
HbA1c levels increased mortality in diabetic patients with MI
[2,3]. Conversely [5], in OPTIMAAL trial (including patients with
myocardial infarction complicated by heart failure) the level of
HbA1c had no impact on mortality among the patients with well-
known diabetes. In consecutive diabetic patients undergoing PCI
[19], HbA1C was not a predictor of cardiac events at one-year
follow-up.
In our investigation, which includes the largest series of
consecutive STEMI patients with known diabetes submitted to
mechanical revascularization, we observed that HbA1c was not
associated with mortality both at short and at long term. Never-
theless, higher HbA1c values (which are detectable in about half of
the entire population) helps in identifying a subset of patients who,
in the early phase of STEMI, show an abnormal glucose response to
stress as indicated by higher values of glucose, a worse glycemic
control during ICCU stay (as inferred by peak glycemia) and a higher
incidence of acute insulin resistance (as indicated by HOMA index).
This subset of patients may deserve a more aggressive treatment for
glucose management. Previous studies performed by others [20] and
us [7,8,11,16,21] showed that admission glycemia and peak glycemia,
are independent predictors for in-hospital mortality in STEMI
patients.
According to our results, in consecutive diabetic STEMI patients
HbA1c values helps in identifying patients who, in the early phase,
develop an abnormal glucose response to acute ischemia as
indicated by higher admission and worse in-hospital glucose control
(as inferred by peak glycemia), though it is not associated with
increased mortality at short and long term. Further studies are
needed to confirm the role of glycated hemoglobin in the risk
stratification of STEMI patients both at short and long terms.
The authors of this manuscript have certified that they comply
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Table 1






Males/Females 64/22 (74.4/25.6%) 67/42 (61.5/38.5%) 0.056
Age (years), mean±SD 71.4±11.4 69.1±10.1 0.149
BMI (kg/m2), mean±SD 26.1±3.8 26.6±4.2 0.334
Estimated GFR (ml/min/1.73 m2),
mean±SD
78.0±38.0 81.3±40.6 0.564
Estimated GFR at nadir
(ml/min/1.73 m2), mean±SD
63.0±29.7 66.7±26.5 0.362
AMI anterior, n (%) 40 (46.5%) 65 (59.6%) 0.116
Killip class n (%) 0.694
I–II 74 (85.7%) 91 (84.3%)
III–IV 12 (14.3%) 18 (15.8%)
LVEF (%), mean±SD 42.5±11.5 41.6±8.9 0.528




Peak glucose (g/l), mean±SD 157±58 252±71 b0.001
Insulinemia (mU/L),
median (IQR)
8.0 (5.0 to 16.3) 19.7 (8.3 to 40.3) b0.001
HOMA index positivity, n (%) 8 (11.4%) 40/(50.0%) b0.001
AST, median (IQR) 41 (26 to 68) 84 (38 to 166) b0.001
ALT, median (IQR) 46 (30 to 138) 39 (25 to 76) 0.051
GGT, median (IQR) 28 (20 to 44) 29 (19 to 45) 0.550
Peak Tn I (ng/ml), median (IQR) 87.4 (42.1 to 239.7) 110.0 (49.1 to 241.0) 0.403
NT-proBNP (pg/ml),
median (IQR)
2210 (798 to 7369) 1676 (671 to 5712) 0.443
Uric acid (mg/dl), mean±SD 5.9±1.8 5.7±1.8 0.293
ESR (mm/h), median (IQR) 24 (12 to 39) 31 (15 to 51) 0.049
Positive CRP, n (%) 50 (60.2%) 47 (46.5%) 0.064
Leucocytes (*103/μl), mean±SD 11.4±4.3 12.0±3.7 0.289










Triglycerides (mg/dl), mean±SD 116±57 122±61 0.533
In-hospital mortality, n (%) 4 (4.7%) 2 (1.8%) 0.408*
BMI: body mass index; AMI: acute myocardial infarction; EF: ejection fraction; PCI:
percutaneous coronary intervention; GFR: glomerular filtration rate; HOMA:
homeostatic model assessment; AST: aspartate transferase; ALT: alanine transferase;
GGT: gamma glutamyl transferase.
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Sudden death in epilepsy
We thank Stollberger and colleagues for their interest in our
paper. Takotsubo syndrome associated with seizure (TSAS) is now a
well established entity, and its relation with sudden unexpected
deaths in epilepsy seems very likely. Stollberger's case control study
adds interesting epidemiological information on the subject.
According to this study, patients with TSAS are younger, more
frequently males and have a higher rate of cardiogenic shock than in
Takotsubo syndrome (TS) associated with other triggers. More
important and more prolonged catecholamine surge release during
seizure may explain these findings. However, in these cases, TS is
often diagnosed because of complications unrelated to epilepsy such
as heart failure, hypotension… which leads to cardiological inves-
tigations. Therefore these reports probably represent only the most
severe cases, and we can easily imagine that numerous “mild” TSAS
are not diagnosed partly because chest pain is rarely reported due to
impaired consciousness, and because ECG is not systematically
performed in these situations. Furthermore, epileptic patients,
especially those suffering from recurrent seizures, may be dis-
charged without any complication since TS has favourable outcome
in most instances.
Stöllberger et al. [1] also pointed out the higher rate of recurrence
in patients suffering from TSAS. Epileptic patients with a history of TS
may be at higher risk of sudden death or other serious complications.
The question of a specific preventive treatment in this population is
of paramount importance.
Larger scale prospective studies would reveal true incidence of
TSAS. They would also specify patient's profile, identify those at high
risk of TSAS, and those who present high risk of recurrence.
On one hand, as reminded by Stollberger et al., localization of the
epileptic focus may matter. Precise electroencephalogram descrip-
tion, morphological and functional MRI would be therefore of great
relevance. On the other hand, TSAS should be diagnosed cautiously. A
patent acute or chronic cardiac disease should not be attributed to
TS. For instance, some acute coronary syndromes may induce
ventricular arrhythmia with subsequent prolonged syncope and
jerky movements.
For all the above-mentioned reasons, studies must be conducted
by multidisciplinary teams of cardiologist and neurologist. The
expertise of both specialties is required to go further in the
understanding of this disease that could affect the management of
seizures in general.
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